Neurocrine Biosciences Announces Initiation Of Phase 1 Clinical Study Evaluating Effects Of NBI-1117570 in Healthy Adults
Portfolio Pulse from Benzinga Newsdesk
Neurocrine Biosciences has announced the initiation of a Phase 1 clinical study evaluating the effects of NBI-1117570 in healthy adults.
September 11, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences has initiated a Phase 1 clinical study for NBI-1117570. This could potentially lead to new product developments and revenue streams for the company.
The initiation of a Phase 1 clinical study is a significant step in drug development. If successful, it could lead to further trials and eventually a new product for Neurocrine Biosciences. This could potentially increase the company's revenue and positively impact its stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100